Self-reported romantic attachment style predicts everyday maternal caregiving behavior at home

Although numerous studies examined how individual differences in mothers' discourse about their early attachment experiences are associated with their caregiving behaviors toward their children, research examining how self-reported romantic attachment style is associated with maternal caregiving has been very limited. To help fill this gap, we examined whether self-reported romantic attachment style is associated with maternal caregiving behaviors observed in home settings. Mother-child interactions were observed for three hours and the mothers completed measures of attachment style and child temperament. Results indicated that attachment-related avoidance, but not attachment-related anxiety, was negatively associated with global maternal sensitivity, after controlling for the child's temperament. Consistent with the propositions of attachment theory, both attachment-related avoidance and anxiety were associated with specific caregiving themes

Hexamethylenetetramine Dinitrate (HDN): The Precursor for RDX Production by Bachmann Process

Hexamethylenetetramine dinitrate (HDN) is a rather weak explosive but is used as a precursor for the synthesis of RDX, one of the most important secondary nitramine explosives. HDN has limited application because of its hygroscopic character. This paper reports on the synthesis and characterization of HDN in high yield and purity by the reaction of hexamine with nitric acid at temperatures below 15 degrees C. It was characterized by FTIR and H-1 NMR spectroscopy, Scanning Electron Microscopy (SEM) and Liquid Chromatography/Mass Spectrometry (LC/MS) measurements. The thermal characteristics of HDN were determined by DSC and TG/DTA. The DSC curve of HDN shows an endothermic peak at 170.5 degrees C corresponding to the melting point of HDN, followed by two exothermic peaks at 174.0 degrees C and 200.5 degrees C due to the decomposition. The differences in the thermal behavior of HDN samples, which were thermally aged at 50 degrees C, 100 degrees C, and 150 degrees C in a nitrogen atmosphere were examined. Additionally, some quantum chemical properties of the nitration of hexamethylenetetramine were calculated

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (p = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference (p = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia